8.32

1.65% -0.14

After Hours: 8.40 0.08 +0.96%

Oric Pharmaceuticals Inc (ORIC)

Overview News Price History Option Chain Financials Discussions Forecast

Oric Pharmaceuticals Inc stock is traded at $8.32, with a volume of 764.85K. It is down -1.65% in the last 24 hours and down -22.75% over the past month. ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Previous Close:

$8.46

Open:

$8.5

24h Volume:

764.85K

Relative Volume:

0.40

Market Cap:

$861.27M

Revenue:

Net Income/Loss:

$-135.21M

P/E Ratio:

-5.8137

EPS:

-1.4311

Net Cash Flow:

$-114.35M

1W Performance:

+2.09%

1M Performance:

-22.75%

6M Performance:

-28.40%

1Y Performance:

+39.83%

1-Day Range:

$8.28

$8.70

1-Week Range:

$7.68

$8.70

52-Week Range:

$5.5148

$14.93

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name

Oric Pharmaceuticals Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(650) 388-5600

Address

240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA

Employee

104

Twitter

Next Earnings Date

2026-05-04

Latest SEC Filings

ORIC's Discussions on Twitter

Compare ORIC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORIC Oric Pharmaceuticals Inc	8.32	875.76M	0	-135.21M	-114.35M	-1.4311
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Initiated	Piper Sandler	Overweight
Nov-20-25	Initiated	Evercore ISI	Outperform
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-04-25	Resumed	Guggenheim	Buy
Jul-08-25	Initiated	Ladenburg Thalmann	Buy
Oct-31-24	Initiated	Wells Fargo	Overweight
Sep-06-24	Initiated	Stifel	Buy
Feb-23-24	Initiated	Cantor Fitzgerald	Overweight
Sep-22-23	Initiated	Wedbush	Outperform
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-06-21	Upgrade	Citigroup	Neutral → Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Aug-13-20	Initiated	Robert W. Baird	Outperform
Aug-06-20	Upgrade	Citigroup	Neutral → Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Citigroup	Neutral
May-19-20	Initiated	Guggenheim	Buy
May-19-20	Initiated	JP Morgan	Overweight
May-19-20	Initiated	Jefferies	Buy

View All

Oric Pharmaceuticals Inc Stock (ORIC) Latest News

May 25, 2026

Trading Systems Reacting to (ORIC) Volatility - Stock Traders Daily

May 25, 2026

May 22, 2026

Cantor Fitzgerald reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada

May 22, 2026

May 21, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - PR Newswire

May 21, 2026

May 20, 2026

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance

May 17, 2026

May 15, 2026

Viking Global (ORIC) reports 8.26M shares; 2.44M warrant rights disclosed - Stock Titan

May 15, 2026

Venrock affiliates report 4.2% stake in ORIC (NASDAQ: ORIC) update - Stock Titan

May 15, 2026

Point72-affiliated filers report 0% ownership in ORIC (ORIC) amendment - Stock Titan

May 15, 2026

T. Rowe Price holds 5.4% of ORIC (ORIC) — 5.39M shares reported - Stock Titan

May 15, 2026

Goldman Sachs upgrades ORIC Pharmaceuticals stock rating to buy By Investing.com - Investing.com Canada

May 15, 2026

Goldman Sachs Upgrades Oric Pharmaceuticals (ORIC) with $15 Pric - GuruFocus

May 15, 2026

May 14, 2026

Oric Pharmaceuticals Inc Enozertinib (ORIC-114) Program Update Call Transcript - GuruFocus

May 14, 2026

Oric Pharmaceuticals faces securities fraud probe after prostate cancer drug update causes 41% stock drop - Pluang

May 14, 2026

Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN

May 14, 2026

May 12, 2026

Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - FinancialContent

May 12, 2026

Pfizer (NYSE: PFE) discloses 3.3% holding in ORIC Pharmaceuticals - Stock Titan

May 12, 2026

May 10, 2026

Number of shareholders of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView

May 10, 2026

May 09, 2026

ORIC: Oric PharmaceuticalsInteractive Chart - Zacks Investment Research

May 09, 2026

Wall Street Zen Downgrades Oric Pharmaceuticals (NASDAQ:ORIC) to Strong Sell - MarketBeat

May 09, 2026

May 08, 2026